Veterinary Diagnostics Market Size, Share & Forecast 2026-2032
Published veterinary diagnostics estimates spread 2.64x at the base year. IDEXX's disclosed $3.4B diagnostics line is 92.6% of the narrowest of them.
$9.5B
$16.5B
9.57%
Global
Executive Summary
Four published estimates of the veterinary diagnostics market put its 2025 or 2026 base somewhere between $3.68 billion and $9.72 billion. That is a 2.64x spread. The published growth rates, by contrast, run only from 7.8% to 10.56% -- a 1.35x spread. Everybody is modelling roughly the same expansion from very different starting points, so a quoted market size in this category is a scope statement rather than a measurement.
For once the scope decision can be settled rather than merely described, because one supplier discloses enough revenue to break the narrow reading outright. IDEXX Laboratories reported CAG Diagnostics recurring revenue of $3,407 million for 2025 in its SEC-filed results. Divide that by MarketsandMarkets' entire global veterinary diagnostics market of $3.68 billion for the same year and one company accounts for 92.6% of it. IDEXX's total company revenue of $4,304 million exceeds that published global market by 17%. Its United States diagnostics revenue alone, $2,215 million, is 60.2% of it. None of that is possible in an industry that also contains Mars' Antech and Heska businesses, Zoetis' diagnostics line, Virbac, Neogen and a long tail of regional laboratories.
Against the broad published readings the same disclosure behaves sensibly: $3,407 million is 39.0% of Mordor Intelligence's $8.73 billion for 2025 and 35.1% of Maximize's $9.72 billion. A largest supplier at a third to two-fifths of a concentrated two-firm industry is a plausible figure. We therefore publish the broad reading -- $9.53 billion for 2026 rising to $16.49 billion by 2032 at 9.57% -- and state in terms a reader can check why the narrow series cannot be the market.
Key Highlights
Published base-year estimates spread 2.64x ($3.68B to $9.72B) while published CAGRs spread only 1.35x (7.8% to 10.56%)
IDEXX's disclosed CAG Diagnostics recurring revenue of $3,407M for 2025 is 92.6% of the narrowest published global market
IDEXX's total company revenue of $4,304M exceeds that same published global market by 17%
IDEXX's US diagnostics revenue alone, $2,215M, is 60.2% of that market and 5.4% of all US veterinary care and product spending
Against the broad reading the same disclosure is 39.0% of Mordor's $8.73B for 2025, a plausible figure for the largest supplier of a concentrated industry
Mars discloses nothing for Antech or Heska and Zoetis discloses no diagnostics dollars, so a large part of the industry is unmeasurable publicly
Mordor's series is the only one of the four whose published base, 2031 mid-point and stated rate reconcile exactly
Market Overview
Market Context
Veterinary diagnostics is not one business but two sold under one name. A practice either runs the test on a benchtop analyser in its own building, buying instruments and a stream of consumables, or it sends the sample to a reference laboratory and buys a service. The published estimates divide almost exactly on whether that second tier is in scope. Mordor Intelligence names software and services as a product type and reference laboratories as an end user. Maximize Market Research includes analytical services and diagnostic imaging and puts laboratories at nearly 49% of its market. Coherent Market Insights includes both services and imaging, the widest definition in the set. MarketsandMarkets segments only by technology and by product -- consumables and instruments -- and its published segmentation contains no services line and no reference-laboratory end user anywhere. So the choice is between the whole testing business, including the laboratory that runs the sample, and the devices and consumables sold into a practice. The structure matters commercially because the money is recurring either way: IDEXX reports customer retention above 97% in its core diagnostics business and places instruments largely to pull consumables behind them.
On the broad definition we adopt -- instruments, kits and reagents, and software and services, sold to clinics, hospitals, reference laboratories and mobile practices, excluding medicines, vaccines and imaging -- the veterinary diagnostics market is $9.53 billion in 2026, projected to $16.49 billion by 2032 at a 9.57% CAGR. A narrower products-and-instruments reading published by MarketsandMarkets puts 2025 at $3.68 billion, but IDEXX's single disclosed diagnostics revenue line is 92.6% of that figure and its total revenue exceeds it, so the narrow series cannot be the market. The spread across published bases is 2.64x; the spread across published growth rates is only 1.35x.
Market Stage
Growth
Adoption Level
Routine in companion animal practice; consolidating in reference laboratories
Key Trends
Market Forecast & Data
Base Year (2026)
$9.5B
Forecast (2032)
$16.5B
CAGR (2026-2032)
9.57%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $9.53B |
| 2027 | $10.44B |
| 2028 | $11.44B |
| 2029 | $12.54B |
| 2030 | $13.74B |
| 2031 | $15.05B |
| 2032 | $16.49B |
The headline is Mordor Intelligence's own published series: $8.73 billion for 2025, $9.53 billion for 2026, $15.05 billion for 2031 and a 9.57% CAGR for 2026-2031, re-read from the publisher's page on 16 October 2026. The 2026 base here is Mordor's own published figure, not a derivation. The 2032 endpoint continues Mordor's own stated rate one year past its own horizon: 9.53 x 1.0957^6 = 16.49. Interpolating back, the 2031 point lands on 15.05, which is Mordor's published value to the cent -- this is the only series of the four whose base, mid-horizon value and rate reconcile exactly. It was chosen because it is the only estimate in the set with a fully stated scope, naming both what is in and what is out, and because it was read from the publisher's own page where the Coherent and Maximize figures came through a distributor listing and a newswire reproduction. Coherent's $9.68 billion for 2026 sits within 1.6% of it despite additionally including imaging, which is the strongest corroboration available here. The intermediate years are interpolation at a constant rate, not separately sourced observations. Readers should note that the growth rates in this category barely disagree; it is the base that moves, and it moves on whether laboratory services are counted.
Market Dynamics
- A consumable-led revenue model in which placed instruments generate recurring reagent and assay demand for years afterwards
- Rising companion animal medicalisation: US pet owners spent $41.0 billion on veterinary care and product sales in 2025, up 3% on 2024 (APPA)
- Corporate consolidation of practices and laboratories, which raises diagnostic utilisation per visit and standardises test menus
- Molecular and point-of-care assay menus expanding what can be run in the clinic rather than sent out
- Reported customer retention above 97% in the largest supplier's core diagnostics business, which compounds installed-base growth
Market Segmentation
By Type
- Instruments and analysers
- Kits, reagents and consumables
- Software and services
- Reference laboratory services
By End User
- Veterinary hospitals and clinics
- Reference laboratories
- Ambulatory and mobile practices
- Research institutes
By Application
- Immunodiagnostics
- Clinical biochemistry
- Molecular diagnostics
- Haematology
- Urinalysis and parasitology
Competitive Landscape
IDEXX Laboratories
United States
The only US-listed pure-play in the category and the only major supplier that discloses its diagnostics revenue outright. Reported CAG Diagnostics recurring revenue of $3,407 million for 2025 against total company revenue of $4,304 million, of which $2,215 million of diagnostics recurring revenue was in the United States. Operates 80 reference laboratory facilities worldwide and reports customer retention above 97% in core diagnostics. Dividing its disclosed line by third parties' published market totals gives 39.0% of Mordor's $8.73 billion and 92.6% of MarketsandMarkets' $3.68 billion for 2025; both are our own arithmetic on differently constructed numbers, and IDEXX has never published a market share.
Mars Petcare, Science and Diagnostics division (Antech, Heska)
United States
Antech Diagnostics is of comparable scale to IDEXX in reference laboratory work. Mars acquired Heska in a deal valued at about $1.3 billion, closing 13 June 2023, and placed it alongside Antech. Mars is privately held and publishes no divisional revenue, so neither business has disclosed revenue since. Heska's last disclosed full year as a listed company was 2022, at $257.3 million of total company revenue, which is used here only as a floor on what Mars absorbed.
Zoetis
United States
Reported total revenue of $9,467 million for 2025, with published tables stopping at Companion Animal ($6,587 million), Livestock ($2,764 million) and Contract Manufacturing and Human Health ($116 million). No diagnostics revenue is disclosed in dollars. Management stated diagnostics grew 13% operationally in 2025, with US companion animal diagnostics up 14%, citing the Vetscan OptiCell launch and an expanded Imagyst menu. Acquired Veterinary Pathology Group, a UK and Ireland laboratory network, in November 2025.
Virbac
France
Named as a supplier into the category alongside Neogen, Thermo Fisher's animal health business and bioMerieux. No diagnostics-specific revenue line was identified for it in this research pass, and none is asserted.
Recent Developments
Reported full-year 2025 revenue of $4,303,702 thousand, up 10% reported and organic, with CAG Diagnostics recurring revenue of $3,407,199 thousand, and guided 2026 revenue to $4,632-$4,720 million with CAG Diagnostics recurring revenue growth of 8.6%-10.6% reported.
Stated at its full-year 2025 results that diagnostics revenue grew 13% operationally in 2025, with US companion animal diagnostics up 14% and international up 11%, attributing growth to the Vetscan OptiCell launch and an expanded Imagyst test menu, without publishing a dollar base.
Acquired Veterinary Pathology Group, a veterinary diagnostic laboratory network in the United Kingdom and Ireland, in November 2025, extending its reference laboratory footprint alongside its in-clinic Vetscan and Imagyst platforms.
Completed the acquisition of Heska Corporation on 13 June 2023 in a deal valued at about $1.3 billion at $120 per share, folding Heska into Mars Petcare's Science and Diagnostics division alongside Antech and removing the industry's second public diagnostics disclosure.
Regulatory Landscape
Research Methodology
Primary research
- No primary interviews were conducted for this edition. This report is a synthesis of company disclosures, public registers and published third-party estimates, and is labelled as such rather than implying fieldwork that did not occur.
Secondary research
- IDEXX Laboratories, Q4 and full-year 2025 results, filed as exhibit 99.1 to a Form 8-K on 2 February 2026, re-read from the SEC filing on 16 October 2026
- Zoetis Inc., Q4 and full-year 2025 results (11 February 2026) and Form 10-K for the year ended 31 December 2025
- American Pet Products Association, 2026 State of the Industry figures for 2025: US pet industry expenditure $158.0 billion, veterinary care and product sales $41.0 billion
- American Veterinary Medical Association, 2025 Pet Ownership and Demographics Sourcebook (via trade-press summaries) and 2025 Report on the Economic State of the Veterinary Profession
- Mordor Intelligence, Veterinary Diagnostics Market (data current as of January 2026); Coherent Market Insights (March 2026, via Global Information Inc.); Maximize Market Research (25 March 2026, via PRNewswire); MarketsandMarkets report 693 (July 2025)
- Heska Corporation's last disclosed full year as a listed company (2022 total revenue $257.3 million) and trade-press coverage of the Mars acquisition closing 13 June 2023
Validation: Market size is taken from published third-party estimates, attributed by name, and presented as published estimates rather than verified measurements. The ratios in this report are a grounding test: IDEXX's SEC-filed CAG Diagnostics recurring revenue of $3,407 million for 2025 was divided by each publisher's base-year total, giving 39.0% of Mordor's $8.73 billion and 92.6% of MarketsandMarkets' $3.68 billion, while IDEXX's total revenue of $4,304 million exceeds the latter outright and its US-only diagnostics revenue of $2,215 million is 60.2% of it. A second check set the same US figure against APPA's $41.0 billion of US veterinary care and product sales, giving 5.4%. These tests establish that the narrow published series cannot be the market; they do not establish the correct size for either scope. Dividing one company's revenue line by a third party's market total compares differently constructed numbers: IDEXX's diagnostics line includes reference laboratory services, consumables and rapid assays, which is wider than diagnostic products and narrower than its total revenue. Heska's $257.3 million is a 2022 whole-company figure, Antech's revenue is not published at all, Zoetis publishes diagnostics growth rates but no dollar base, and the AVMA pet populations used for the per-animal scale check were read from trade-press summaries of a paid publication rather than the Sourcebook itself. No vendor market share is published because none is disclosed, and no regional or country split is published because no named source gives one.
Strategic Takeaways
Before quoting a veterinary diagnostics market size, establish whether reference laboratory services are inside it -- that single decision moves the base by 2.64x
one company's disclosed diagnostics line is 92.6% of it
Growth rate is the stable part of the published literature here; the disagreement is entirely about the starting point
Any vendor share percentage in this category is an estimate, because two of the four largest businesses disclose no diagnostics revenue at all
The revenue is recurring rather than capital, so instrument placement counts matter more as a forward indicator than instrument revenue does
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Life SciencesAntimicrobial Resistance Diagnostics Market$5.3B · 6.26% CAGR
- Medical DevicesPoint-of-Care Diagnostics Market$35.2B · 7% CAGR
- Medical ImagingAI in Cancer Diagnostics Market$1.0B · 11.16% CAGR
- Life SciencesLiquid Biopsy Market$8.0B · 13.91% CAGR
- Life SciencesPharmacogenomics Market$6.8B · 6.6% CAGR
- Life SciencesProteomics Market$35.0B · 13% CAGR